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Sedative and analgesic efficacy of three intravenous doses of medetomidine, i.e., 4, 
5 and 6 µg/kg BW was studied in six goats. A randomized cross over experimental 
design was used. Onset of sedation, onset of optimal sedation, duration of optimal 
sedation and degree of sedation were measured and found to be dose dependent. 
Dose 4 µg/kg produced light sedation whereas 5 and 6 µg/kg produced moderate 
and deep sedation, respectively. Total duration of sedation was 60.58±2.21, 
83.50±3.75 and 104.33±4.30 min after administration of 4, 5 and 6 µg/kg 
medetomidine, respectively. The duration of sedation was significantly (P≤0.01) 
longer with 6 µg/kg as compared to 4 and 5µg/kg. Onset and duration of analgesia 
were dose dependent. The mean values for onset of analgesia were 25.00±3.00, 
24.16±1.74 and 12.00±1.50 min and duration of analgesia was 8.00±2.00, 
17.16±1.81 and 31.50±2.61 min after administration of 4, 5 and 6 µg/kg 
medetomidine, respectively. Skin analgesia and muscle relaxation were produced in 
all animals with higher doses (5 and 6 µg/kg) and only in 2 animals with 4 µg/kg of 
medetomidine. It was concluded that medetomidine is a highly potent drug which 
can be effectively used in the dose rates of 4 to 5µg /kg I/V for sedation in goats. 
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INTRODUCTION 
 
Medetomidine (Domitor®, Orion Corporation, Espoo, 
Finland), is a new sedative drug developed primarily for use 
in dogs and cats. It is very potent, efficacious and selective 
alpha2 agonist (Lumb and Jones, 1996). Medetomidine can 
be administered by intravenous, intramuscular or 
subcutaneous injection. It produces a reliable degree of 
sedation, muscle relaxation and analgesia in various species 
of animals (Hall and Clarke, 1991). Mostly the drug has 
been used in dogs and cats (Clarke and  England, 1989; 
Golden et al., 1996). However few reports of its use in sheep 
(Mohammad  et al., 1993;  Muge et al.,1996 ; Celly 
et.al.,1999), cattle (Arnemo and Soli, 1993; Bryant et 
al.,1998 ),  buffalo calves (Kalhoro et al., 2000) and in goats 
(Mohammad et al., 1989; Carroll, et al., 2005; Kinjavdekar 
et al., 2007) have also been  published.  
There has been no comprehensive study on the sedative 
and analgesic efficacy of various doses of medetomidine in 
goats. It was, therefore, decided to conduct a study on 
various dose rates and sedative and analgesic effects of 
medetomidine in goats. 
MATERIALS AND METHODS 
 
Six female Barri goats having 10 to 16 months of age 
and 30 to 45 kg BW were used in this study. The goats 
were purchased from local market. Animals were kept at 
the Indoor Patient Ward, Department of Surgery and 
Obstetrics, Sindh Agriculture University, Tandojam 
during the experiments. Animals were allowed to adapt to 
their surroundings before start of experiments and were 
left loose for exercise in the mornings and evenings. 
Goats were fed alpha alpha (Medicago sativa) and 
burseem (Trifolium alexandrinum) fodders. All goats were 
ear tagged, dewormed with Oxafax
R (Glaxo, Wellcome 
Pakistan) (5 mg/kg) and vaccinated with contagious 
caprine pleuropneumonia vaccine (0.5 ml s/c) (Veterinary 
Research Institute, Brewery Road, Quetta, Pakistan), and 
enterotoxaemia vaccine (1 ml/sc) (Veterinary Research 
Institute, Brewery Road, Quetta, Pakistan). 
 
Experimental design  
A randomized cross over experimental design was 
used. Each of six goats received medetomidine in 3 
different doses i.e. 4, 5 and 6 µg/kg WB intravenously. At 
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least 10 days interval was allowed between two treatments 
in each animal. Immediately after administration of 
medetomidine, various parameters of sedation and 
analgesia such as onset of sedation, onset of optimal 
sedation, total duration of sedation, level of sedation and 
onset and duration of analgesia were recorded. The 
occurrence of muscle relaxation and recumbency, if any, 
were also recorded. Level of sedation was quantified as 0 
(no sedation; goat appeared alert), 1 (light sedation; goat 
standing quietly, staggering a bit with its head lowered 
below shoulders but above knees), 2 (moderate sedation; 
goat appeared drowsy, and staggering with its head lowered 
beyond knees) and 3 (deep sedation; goat lowering its head 
beyond knees, staggering and eventually going into lateral 
recumbency). 
 
Statistical analysis  
Statistical analysis was performed using the computer 
program Graph Pad Instat; GPIS (1990, Graph pad 
Software, San Diego, USA) and one way analysis of 
variance and Tukey-Kramer Multiple Comparison test.  
 
RESULTS 
 
Sedative effects 
The onset of sedation was dose dependent, with 
higher dose of medetomidine (6 µg/kg) producing more 
rapid effect.  Statistically sedation occurred significantly 
quicker (P≤0.01) with 5 and 6 µg/kg as compared to 4 
µg/kg. There was no significant difference in onset of 
sedation with 5 and 6 µg/kg of medetomidine. The onset 
of optimal sedation was more rapid with the increasing 
dose. Statistically onset of optimal sedation was 
significantly rapid (P≤0.01) with 6 µg/kg as compared to 
4 and 5 µg/kg. Comparison of 4 with 5 µg/kg showed no 
significant difference in onset of optimal sedation (Table 
1). 
 
Table 1: Sedative and analgesic effects of medetomidine in goats 
Medetomidine Dose (µg/kg b wt) 
Parameter 
4 5 6 
Onset of sedation 
(sec) 
  250±40.00a   120±15.96b   57.50±7.15b 
Onset of optimal 
sedation (min) 
22.50±2.50a 21.50±1.54a    10.00±1.50b 
Duration of optimal 
sedation (min) 
11.50±1.50  23.83±2.21    42.50±2.59 
Total duration of 
sedation (min) 
60.58±2.21a 83.50±3.75a  104.33±4.30b 
Level of sedation  Light  Moderate  Deep 
Onset of skin 
analgesia (min) 
25.00±3.00a 24.16±1.74a  12.00±1.50b 
Total duration of 
skin analgesia (min) 
  8.00±2.00a  17.16±1.81a  31.50±2.61b 
Duration of 
recumbency (min) 
No 
recumbency 
39.33±3.87a 55.16±4.34b 
Values (Mean±SE) bearing different letters in a row differ 
significantly (P≤01). 
 
Medetomidine produced dose dependent effects on 
duration of optimal sedation and total duration of sedation. 
The duration was increased with increasing dose of 
medetomidine. There was significant difference in total 
duration of sedation with 4, 5 and 6 µg/kg of medetomidine.  
Statistically total duration of sedation was significantly 
longer (P≤0.01) with 6 µg/kg as compared to 4 and 5 µg/kg.  
The degree of sedation was light in all animals treated 
with 4 µg/kg of medetomidine. 5 µg/kg of medetomidine 
produced variable results. Three animals (No. 1, 3 and 6) 
showed moderate sedation, two animals (No. 4 and 5) deep 
sedation and one animal (No. 2) light sedation. 6 µg/kg of 
medetomidine produced signs of deep sedation in all 
animals. Statistical analysis showed that the degree of 
sedation was significantly different (P≤0.01) with all three 
doses. 
The dose rate of 4 µg/kg I/V induced no recumbency in 
any animal, where as higher dose (6 µg/kg) produced 
recumbency in all animals. Dose 5 µg/kg produced 
recumbency in only two animals.  Analysis of variance 
showed that the duration of recumbency was significantly 
different. Further analysis by Tukey-kramer multiple 
comparison test showed that the duration of recumbency 
was significantly longer (P≤0.01) with 6 µg/kg than with 5 
µg/kg of medetomidine. 
 
Analgesic effects 
The dose rate of 4 µg/kg produced skin analgesia in 
only 2 animals (Nos.1and 4), where as higher doses (5 and 6 
µg/kg) produced analgesia in all animals. The onset and 
duration of analgesia were dose dependent. The duration of 
analgesia was increased with increasing dose of 
medetomidine (Table 1). Analysis of variance showed that 
the duration of skin analgesia was significantly different 
with 3 doses. Further analysis by Tukey-kramer multiple 
comparison test showed that the duration of analgesia was 
significantly longer (P≤0.01) with 6µg/kg as compared to 4 
and 5 µg/kg b wt of medetomidine. 
 
DISCUSSION 
 
In the present study, medetomidine produced dose 
dependent levels of sedation in goats. Light, moderate and 
deep sedation were produced with 4, 5 and 6 µg/kg 
medetomidine, respectively. Deep and rapid onset of 
sedation has been reported in dogs with 20 and 40 fg/kg 
(I/m) of medetomidine (Clarke and England, 1989). Higher 
dose (6 µg/kg) produced recumbency in all animals. The 
onset of sedation in goats was dose dependant as has been 
reported with medetomidine in buffalo calves (Kalhoro et 
al., 2000). Vainio et al. (1989) reported that sedation 
occurred within 1.5 minutes of administration of 
medetomidine in dogs. 
The duration of optimal sedation and total duration of 
sedation were both significantly longer with higher doses (5 
and 6 µg/kg) of medetomidine. Higher doses (5 and 6 
µg/kg) produced quicker and longer duration of skin 
analgesia in goats.  Similar observations have been reported 
in other species such as in dogs (Clarke and England, 1989; 
Vainio et al., 1989) and in buffalo calves (Shahani, 1998; 
Kalhoro et al., 2000). 
It is concluded that medetomidine is a highly potent 
drug which produces effective sedation in very small doses. 
Its sedative and analgesic effects are all dose dependent. The 
dose rates of 4 to 5 µg/kg b wt can be safely used for light to 
moderate sedation in goats.  Pak Vet J, 2011, 31(3): 257-259. 
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